Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells.
Animals
Chromatography, Affinity
/ methods
Dasatinib
/ pharmacology
Dogs
HEK293 Cells
Humans
Janus Kinases
/ antagonists & inhibitors
K562 Cells
Mice
Microspheres
Monocytes
/ metabolism
Protein Binding
Protein Kinase Inhibitors
/ pharmacology
Proteome
/ chemistry
Proteomics
/ methods
Sepharose
/ analogs & derivatives
Substrate Specificity
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 Oct 2019
02 Oct 2019
Historique:
received:
18
04
2019
accepted:
05
09
2019
entrez:
4
10
2019
pubmed:
4
10
2019
medline:
29
10
2020
Statut:
epublish
Résumé
Kinobeads are a set of promiscuous kinase inhibitors immobilized on sepharose beads for the comprehensive enrichment of endogenously expressed protein kinases from cell lines and tissues. These beads enable chemoproteomics profiling of kinase inhibitors of interest in dose-dependent competition studies in combination with quantitative mass spectrometry. We present improved bead matrices that capture more than 350 protein kinases and 15 lipid kinases from human cell lysates, respectively. A multiplexing strategy is suggested that enables determination of apparent dissociation constants in a single mass spectrometry experiment. Miniaturization of the procedure enabled determining the target selectivity of the clinical BCR-ABL inhibitor dasatinib in peripheral blood mononuclear cell (PBMC) lysates from individual donors. Profiling of a set of Jak kinase inhibitors revealed kinase off-targets from nearly all kinase families underpinning the need to profile kinase inhibitors against the kinome. Potently bound off-targets of clinical inhibitors suggest polypharmacology, e.g. through MRCK alpha and beta, which bind to decernotinib with nanomolar affinity.
Identifiants
pubmed: 31578349
doi: 10.1038/s41598-019-50335-5
pii: 10.1038/s41598-019-50335-5
pmc: PMC6775116
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Proteome
0
Sepharose
9012-36-6
Janus Kinases
EC 2.7.10.2
Dasatinib
RBZ1571X5H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14159Références
Nature. 2014 May 29;509(7502):582-7
pubmed: 24870543
Nat Methods. 2009 Oct;6(10):741-4
pubmed: 19749761
Mol Genet Metab. 2011 Apr;102(4):418-29
pubmed: 21237683
Trends Mol Med. 2005 Dec;11(12):546-54
pubmed: 16271512
J Proteome Res. 2013 Sep 6;12(9):4005-17
pubmed: 23901793
J Proteome Res. 2013 Aug 2;12(8):3586-98
pubmed: 23768245
Cell Commun Signal. 2014 Oct 05;12:54
pubmed: 25288205
Cancer Res. 2006 Mar 1;66(5):2562-9
pubmed: 16510573
Science. 2017 Dec 1;358(6367):
pubmed: 29191878
N Engl J Med. 2002 Aug 15;347(7):472-80
pubmed: 12181401
Biochem J. 2014 Apr 1;459(1):171-80
pubmed: 24467396
Structure. 2016 Mar 1;24(3):401-11
pubmed: 26853940
Anal Chem. 2012 Aug 21;84(16):7188-94
pubmed: 22881393
J Med Chem. 2004 Mar 25;47(7):1719-28
pubmed: 15027863
Immunol Rev. 2009 Mar;228(1):273-87
pubmed: 19290934
Lancet. 2005 Mar 19-25;365(9464):1054-61
pubmed: 15781101
Science. 2002 Dec 6;298(5600):1912-34
pubmed: 12471243
Anal Chem. 2011 Dec 1;83(23):8959-67
pubmed: 22017476
ACS Chem Biol. 2012 Nov 16;7(11):1858-65
pubmed: 22908928
N Engl J Med. 2012 Aug 9;367(6):495-507
pubmed: 22873530
Sci Transl Med. 2017 Apr 26;9(387):
pubmed: 28446690
J Med Chem. 2006 Nov 16;49(23):6819-32
pubmed: 17154512
Mol Cell. 2008 Aug 8;31(3):438-48
pubmed: 18691976
Bioorg Med Chem. 2012 Mar 15;20(6):1973-8
pubmed: 22130419
ACS Chem Biol. 2016 May 20;11(5):1245-54
pubmed: 26863403
Expert Opin Pharmacother. 2012 Nov;13(16):2397-407
pubmed: 23051187
J Am Chem Soc. 2017 Jan 18;139(2):680-685
pubmed: 28051857
Nature. 2018 Aug;560(7717):192-197
pubmed: 30046105
N Engl J Med. 2017 Feb 16;376(7):652-662
pubmed: 28199814
Nat Methods. 2014 Mar;11(3):319-24
pubmed: 24487582
Clin Transl Sci. 2009 Feb;2(1):15-25
pubmed: 20376335
Nat Chem Biol. 2009 Sep;5(9):616-24
pubmed: 19690537
Cancer Cell. 2005 Apr;7(4):387-97
pubmed: 15837627
Oncogene. 1994 Aug;9(8):2415-23
pubmed: 7518579
Nat Chem Biol. 2012 Apr 29;8(6):576-82
pubmed: 22544264
Mol Cancer. 2018 Feb 19;17(1):48
pubmed: 29455673
N Engl J Med. 2015 Jan 29;372(5):426-35
pubmed: 25629741
J Proteome Res. 2017 Mar 3;16(3):1216-1227
pubmed: 28102076
Bioorg Med Chem Lett. 2005 Jul 15;15(14):3402-6
pubmed: 15950465
J Proteome Res. 2013 Jul 5;12(7):3104-16
pubmed: 23692254
Leukemia. 2011 Jan;25(1):89-100
pubmed: 20944678
Mol Cell Biol. 1991 Apr;11(4):2057-65
pubmed: 1848670
Cancer Res. 1999 Dec 15;59(24):6145-52
pubmed: 10626805
Nat Biotechnol. 2008 Jan;26(1):127-32
pubmed: 18183025
Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77
pubmed: 24818516
Nat Rev Drug Discov. 2017 Jun;16(6):424-440
pubmed: 28280261
Nat Chem Biol. 2015 Aug;11(8):536-41
pubmed: 26196764
Science. 2014 Oct 3;346(6205):1255784
pubmed: 25278616
J Proteome Res. 2015 Mar 6;14(3):1574-86
pubmed: 25660469
Nat Biotechnol. 2007 Sep;25(9):1035-44
pubmed: 17721511
Nat Cell Biol. 2005 Mar;7(3):255-61
pubmed: 15723050
ACS Chem Biol. 2013 Mar 15;8(3):599-607
pubmed: 23215245
Chem Biol. 2011 Jun 24;18(6):699-710
pubmed: 21700206
J Lab Autom. 2016 Feb;21(1):133-42
pubmed: 26169024
J Med Chem. 2008 Sep 25;51(18):5663-79
pubmed: 18800763
ACS Chem Biol. 2013 Jan 18;8(1):96-104
pubmed: 23276252
Expert Opin Investig Drugs. 2015 Jan;24(1):95-110
pubmed: 25315907
Anal Chem. 2014 Apr 1;86(7):3594-601
pubmed: 24579773
Future Med Chem. 2016 Sep;8(13):1537-51
pubmed: 27572962
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187